Efficacy and Safety Evaluation of Astegolimab in Chronic Obstructive Pulmonary Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study

The primary objective of this study is to evaluate the effect of **astegolimab** compared with placebo on the annualized rate of moderate and severe acute exacerbations of **Chronic Obstructive Pulmonary Disease (COPD)** over 52 weeks of treatment. This is clinically relevant as reducing the frequency of exacerbations can significantly improve patient outcomes, decrease healthcare utilization, and enhance the quality of life for individuals with COPD.

Secondary objectives include: - Evaluating the effect of astegolimab compared with placebo on the time to first moderate or severe COPD exacerbation. - Assessing the impact on St George’s Respiratory Questionnaire scores. - Measuring changes in post-bronchodilator forced expiratory volume in 1 second (FEV1). - Evaluating the effect on Evaluating Respiratory Symptoms in COPD (E-RS:COPD). - Determining the annualized rate of severe COPD exacerbations. - Assessing the safety profile of astegolimab compared with placebo. - Characterizing the pharmacokinetic (PK) profile of astegolimab. - Evaluating the immune response to astegolimab.

The clinical trial involves a total of **827 participants** diagnosed with **Chronic Obstructive Pulmonary Disease (COPD)**. The study population includes both male and female subjects, aged between 40 and 90 years. Participants were selected based on a documented physician diagnosis of COPD for at least 12 months and a history of frequent exacerbations, defined as having had two or more moderate or severe exacerbations within a 12-month period in the 24 months prior to screening. Eligible participants are current or former smokers with a minimum of 10 pack-year history and have a post-bronchodilator FEV1 between 20% and 80% of the predicted normal value at screening. The trial includes individuals on optimized, stable, standard-of-care COPD maintenance therapy, such as inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA) plus LABA, or ICS plus LAMA plus LABA, for at least 4 weeks prior to screening, with no anticipated changes in therapy throughout the study. The trial population is not limited to any specific gender, and it includes vulnerable populations. Lifestyle considerations such as diet and physical activity are not specified in the available data.

The clinical trial is a **Phase IIb**, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of astegolimab in patients with **Chronic Obstructive Pulmonary Disease (COPD)**. The primary objective is to assess the effect of astegolimab compared to placebo on the annualized rate of moderate and severe acute exacerbations of COPD over a 52-week treatment period. The trial is expected to conclude by March 2025, with recruitment having commenced in February 2022.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age (40-90 years), documented diagnosis of COPD for at least 12 months, and a history of frequent exacerbations. Eligible participants must also have a post-bronchodilator FEV1 between 20% and 80% of the predicted normal value and a smoking history of at least 10 pack-years. The study will include follow-up visits at regular intervals to monitor the participants' health status, adherence to the study protocol, and any adverse events. The end-of-study visit will occur at the conclusion of the 52-week treatment period.

Participant involvement is expected to last approximately 52 weeks, with conditions for early termination including non-compliance with the study protocol, withdrawal of consent, or the occurrence of adverse events that necessitate discontinuation. The primary endpoint is the annualized rate of moderate and severe COPD exacerbations over the treatment period. Secondary endpoints include time to first moderate or severe exacerbation, changes in health-related quality of life (HRQoL) as measured by the St. George's Respiratory Questionnaire-COPD, and changes in post-bronchodilator FEV1, among others. The study will also assess the incidence and severity of adverse events, serum concentration of astegolimab, and the prevalence of anti-drug antibodies.

The clinical trial involves the evaluation of several treatments for patients with **Chronic Obstructive Pulmonary Disease (COPD)**. The primary experimental medication is a **monoclonal antibody** identified by the sponsor product code RO 718-7807/F03-02, developed by F. Hoffmann-La Roche Ltd. This investigational drug is administered to assess its efficacy in reducing the annualized rate of moderate and severe acute exacerbations of COPD over a 52-week treatment period. The pharmaceutical form, dosage, route, and frequency of administration are not specified in the provided data.

In addition to the experimental monoclonal antibody, the study includes several **auxiliary treatments**. These include a **long-acting muscarinic antagonist**, an **inhaled corticosteroid**, and a **long-acting beta2-agonist**. These medications are chemically derived and are commonly used in the management of COPD to help control symptoms and prevent exacerbations. The specific pharmaceutical forms, dosages, routes, and frequencies of administration for these auxiliary treatments are not detailed in the available information.

The trial also incorporates a **placebo** as a comparator treatment to evaluate the efficacy of the experimental monoclonal antibody. The placebo is used to ensure that any observed effects can be attributed to the investigational drug rather than other factors. Details regarding the administration of the placebo, including its form and dosing schedule, are not provided.

Participant compliance with the treatment regimen is monitored throughout the study to ensure adherence to the dosing schedules and to accurately assess the efficacy and safety of the investigational and auxiliary treatments. The trial is conducted in a double-blind manner, meaning neither the participants nor the investigators know which treatment the participants are receiving, to minimize bias and ensure the integrity of the study results.

The efficacy of astegolimab in patients with **Chronic Obstructive Pulmonary Disease (COPD)** will be assessed through a series of primary and secondary endpoints over a 52-week treatment period. The primary endpoint is the annualized rate of moderate and severe COPD exacerbations. Secondary endpoints include the time to the first moderate or severe exacerbation, absolute change from baseline in Health-Related Quality of Life (HRQoL) as measured by the St. George's Respiratory Questionnaire-COPD (SGRQ-C) total score, and the proportion of patients with an improvement in HRQoL, defined as a decrease from baseline of ≥4 points in the SGRQ-C total score at Week 52.

Additional secondary endpoints involve the absolute change from baseline in post-bronchodilator Forced Expiratory Volume in one second (FEV1) at Week 52, the absolute change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score, and the annualized rate of severe COPD exacerbations. The study will also measure the absolute change from baseline in the five-repetition sit-to-stand test (5STS) time at Week 52, the incidence and severity of adverse events, serum concentration of astegolimab at specified timepoints, and the prevalence and incidence of anti-drug antibodies (ADAs).